Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Tcr2 Therapeutics Inc (TCRR)

Tcr2 Therapeutics Inc (TCRR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 890,362
  • Shares Outstanding, K 33,422
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,600 K
  • 60-Month Beta 2.18
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.50
Trade TCRR with:

Options Overview

Details
  • Implied Volatility 90.48%
  • Historical Volatility 57.24%
  • IV Percentile 8%
  • IV Rank 2.71%
  • IV High 364.48% on 03/18/20
  • IV Low 82.85% on 10/29/20
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 374

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.57
  • Number of Estimates 7
  • High Estimate -0.47
  • Low Estimate -0.83
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.69 +0.16%
on 03/03/21
30.14 -14.63%
on 02/19/21
-0.60 (-2.28%)
since 02/03/21
3-Month
24.25 +6.10%
on 01/27/21
35.86 -28.25%
on 12/14/20
-3.28 (-11.31%)
since 12/03/20
52-Week
5.84 +340.58%
on 03/17/20
35.86 -28.25%
on 12/14/20
+13.77 (+115.13%)
since 03/03/20

Most Recent Stories

More News
TCR(2) Therapeutics to Participate in Two Upcoming Conferences in March

TCR Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an...

TCRR : 25.73 (-3.42%)
TCR(2) Therapeutics to Present at SVB Leerink Global Healthcare Conference

TCR Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial...

TCRR : 25.73 (-3.42%)
TCR(2) Therapeutics Announces Commercial Cell Therapy Leader Shawn Tomasello Joins its Board of Directors

TCR Therapeutics Inc. (Nasdaq: TCRR) ("TCR" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment...

TCRR : 25.73 (-3.42%)
TCR(2) Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock

TCR Therapeutics Inc. (Nasdaq: TCRR) ("TCR" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the pricing...

TCRR : 25.73 (-3.42%)
TCR(2) Therapeutics Announces Proposed Public Offering of Common Stock

TCR Therapeutics Inc. (Nasdaq: TCRR) ("TCR" or the "Company"), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that...

TCRR : 25.73 (-3.42%)
TCR(2) Therapeutics Announces 2021 Strategic Priorities and Milestones

- Additional data from ongoing gavo-cel Phase 1/2 trial to be presented in 1H21

TCRR : 25.73 (-3.42%)
TCR(2) Therapeutics to Present at J.P. Morgan Healthcare Conference

TCR Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that Garry Menzel, Ph.D., President...

JPM : 152.91 (+1.93%)
TCRR : 25.73 (-3.42%)
Thinking about buying stock in Tcr2 Therapeutics, Inovio Pharmaceuticals, BioLineRx, Plug Power, or Arbutus Biopharma?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TCRR, INO, BLRX, PLUG, and ABUS.

ABUS : 3.64 (-4.96%)
INO : 9.56 (-4.59%)
TCRR : 25.73 (-3.42%)
BLRX : 2.90 (-5.84%)
PLUG : 43.81 (-10.19%)
TCR(2) Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

- TC-210 induced tumor regression in all of the first eight patients

TCRR : 25.73 (-3.42%)
Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the...

TCRR : 25.73 (-3.42%)
BDTX : 25.64 (-3.57%)
DVA : 102.78 (-0.71%)
RGLS : 1.2700 (-5.22%)
STOK : 59.30 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 28.79
2nd Resistance Point 28.16
1st Resistance Point 26.95
Last Price 25.73
1st Support Level 25.10
2nd Support Level 24.47
3rd Support Level 23.26

See More

52-Week High 35.86
Last Price 25.73
Fibonacci 61.8% 24.39
Fibonacci 50% 20.85
Fibonacci 38.2% 17.31
52-Week Low 5.84

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar